Buy or sell BioTheryX stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

BioTheryX Stock

BioTheryX is a clinical-stage biopharmaceutical company that focuses on the development of therapies for hematological malignancies.

About BioTheryX Stock

BioTheryX focuses on the development of therapies for hematological malignancies. It intends to leverage its extensive experience and proven commercial success to deliver efficacious therapies to patients with unmet medical needs more quickly and less expensively than the biomedical industry traditionally can and does. To do so, they are exploiting enhanced biology-driven models to identify effective core molecules that can be rapidly exploited using focused and prioritized chemistry approaches coupled with clinically proven translational approaches targeted for cancer and immune dysfunction. The company was founded in 2007 and is headquartered in Chappaqua, New York.

Funding History

June 2014$1.0M
September 2014$150K
May 2015$500K
July 2020$35.0M
May 2021$18.0M
May 2021$92.0M

Management

Chief Business Officer

Sahm Nasseri

Chief Financial Officer

Jeff Caravella

Co-Founder, President & Board Member

Lawrence Zaslow

Co-Founder, Chief Development Officer & Chairman & Owner

David Stirling

Board Member

Robert Platek

Chief Executive Officer

Philippe Drouet

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 280K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo